RIPK1 and Alzheimer disease: In AD models, inhibition of RIPK1 signaling reduces M1 microglial markers and inflammatory cytokines, promoting microglial phenotypic shift toward the anti-inflammatory, Aβ-clearing M2 state (Zhang et al. 2023).